Thus, finding the modalities to control appropriate levels of PINK1/Parkin-mediated mitophagy activation may represent a potential therapeutic option to intervene the aging-associated pathogenesis of COPD and IPF. Here, PRKN is linked to chronic obstructive pulmonary disease.